Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Q4 2024 Earnings Call Transcript January 28, 2025 Stryker Corporation beats earnings expectations. Reported EPS is $4.01, expectations were $3.87. Operator: Welcome to the Fourth Quarter 2024 Stryker ...

Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...

Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with venous thromboembolism (VTE) (with significant growth opportunities ...

It delivered a trailing four-quarter average earnings surprise of 24.77%. Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with ...

Inari’s ClotTriever Thrombectomy System Gains Reimbursement Approval in Japan December 2, 2024—Inari Medical, Inc. announced that it has received national reimbursement approval from the Japanese ...